JP2013155195A5 - - Google Patents

Download PDF

Info

Publication number
JP2013155195A5
JP2013155195A5 JP2013099331A JP2013099331A JP2013155195A5 JP 2013155195 A5 JP2013155195 A5 JP 2013155195A5 JP 2013099331 A JP2013099331 A JP 2013099331A JP 2013099331 A JP2013099331 A JP 2013099331A JP 2013155195 A5 JP2013155195 A5 JP 2013155195A5
Authority
JP
Japan
Prior art keywords
amino acid
cysteine
peptide
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013099331A
Other languages
English (en)
Japanese (ja)
Other versions
JP5764613B2 (ja
JP2013155195A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013155195A publication Critical patent/JP2013155195A/ja
Publication of JP2013155195A5 publication Critical patent/JP2013155195A5/ja
Application granted granted Critical
Publication of JP5764613B2 publication Critical patent/JP5764613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013099331A 2009-07-29 2013-05-09 副甲状腺ホルモンを低減する治療剤 Active JP5764613B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22969509P 2009-07-29 2009-07-29
US61/229,695 2009-07-29
US25581609P 2009-10-28 2009-10-28
US61/255,816 2009-10-28
US31363510P 2010-03-12 2010-03-12
US61/313,635 2010-03-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012523061A Division JP5270799B2 (ja) 2009-07-29 2010-07-29 副甲状腺ホルモンを低減する治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014023488A Division JP2014094967A (ja) 2009-07-29 2014-02-10 副甲状腺ホルモンを低減する治療剤

Publications (3)

Publication Number Publication Date
JP2013155195A JP2013155195A (ja) 2013-08-15
JP2013155195A5 true JP2013155195A5 (enExample) 2014-03-27
JP5764613B2 JP5764613B2 (ja) 2015-08-19

Family

ID=43527590

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012523061A Active JP5270799B2 (ja) 2009-07-29 2010-07-29 副甲状腺ホルモンを低減する治療剤
JP2013099331A Active JP5764613B2 (ja) 2009-07-29 2013-05-09 副甲状腺ホルモンを低減する治療剤
JP2014023488A Pending JP2014094967A (ja) 2009-07-29 2014-02-10 副甲状腺ホルモンを低減する治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012523061A Active JP5270799B2 (ja) 2009-07-29 2010-07-29 副甲状腺ホルモンを低減する治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014023488A Pending JP2014094967A (ja) 2009-07-29 2014-02-10 副甲状腺ホルモンを低減する治療剤

Country Status (29)

Country Link
US (11) US8999932B2 (enExample)
EP (5) EP4154900B1 (enExample)
JP (3) JP5270799B2 (enExample)
KR (1) KR101781841B1 (enExample)
CN (2) CN102711789B (enExample)
AU (1) AU2010278897B2 (enExample)
BR (1) BR112012002143B8 (enExample)
CA (1) CA2769525C (enExample)
CY (3) CY1118388T1 (enExample)
DK (2) DK3192520T3 (enExample)
ES (2) ES2607954T3 (enExample)
FR (1) FR17C1009I2 (enExample)
HR (2) HRP20161614T1 (enExample)
HU (3) HUE043838T2 (enExample)
IL (1) IL217749A (enExample)
LT (3) LT3192520T (enExample)
LU (1) LUC00008I2 (enExample)
MX (1) MX2012001213A (enExample)
NO (1) NO2017021I1 (enExample)
NZ (1) NZ597922A (enExample)
PL (2) PL2459208T3 (enExample)
PT (2) PT3192520T (enExample)
RU (1) RU2557654C3 (enExample)
SG (2) SG178143A1 (enExample)
SI (2) SI3192520T1 (enExample)
SM (3) SMT201700014B (enExample)
TW (1) TWI520744B (enExample)
WO (1) WO2011014707A2 (enExample)
ZA (1) ZA201200726B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669914C (en) * 2006-11-16 2017-11-07 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
LT3192520T (lt) 2009-07-29 2019-06-25 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti paratiroidinio hormono lygių sumažinimui
JP5761173B2 (ja) 2010-03-04 2015-08-12 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
CN102781910B (zh) 2010-03-04 2015-03-11 味之素株式会社 烷基胺衍生物
JP5796570B2 (ja) 2010-03-24 2015-10-21 味の素株式会社 グルタミン酸エステル誘導体又はその塩
EP2554165A4 (en) 2010-04-02 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
SI2717896T1 (sl) * 2011-06-08 2017-04-26 Kai Pharmaceuticals, Inc. Terapevtska sredstva za reguliranje serumskega fosforja
MX355063B (es) 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.
US20150126457A1 (en) * 2012-04-17 2015-05-07 Brown University Neuroprotective composition and method of use
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
EP3246017B1 (en) * 2013-06-28 2021-03-24 Amgen Inc. Stable liquid formulation of amg 416 hcl (etelcalcetide)
ME03781B (me) * 2014-04-03 2021-04-20 Amgen Inc Metoda za pripremanje amg 416
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3274360B1 (en) 2015-03-26 2020-05-06 Amgen Inc. Solution phase method for preparing etelcalcetide
US9336841B1 (en) * 2015-04-16 2016-05-10 Taiwan Semiconductor Manufacturing Co., Ltd. Pipeline register with data alignment therein
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism
JP2021501793A (ja) * 2017-11-07 2021-01-21 アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法
WO2019124411A1 (ja) 2017-12-20 2019-06-27 Ｅａファーマ株式会社 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物
KR101933685B1 (ko) * 2018-06-29 2018-12-28 주식회사 에스알바이오텍 약물이 코팅된 마이크로 니들 및 이의 제조방법
EP3906059A4 (en) * 2018-11-02 2022-06-22 Ampersand Biopharmaceuticals, Inc. MANAGING THE RISK OF CATION OVERLOAD AND ELECTROLYTE BALANCE WITH TOPICALLY APPLIED BUFFER
EP3950058A4 (en) 2019-04-03 2023-01-04 EA Pharma Co., Ltd. PHARMACEUTICAL COMPOSITION WITH FAVORABLE STABILITY
WO2021115272A1 (zh) * 2019-12-09 2021-06-17 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
WO2021226064A1 (en) * 2020-05-04 2021-11-11 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
JP7440132B2 (ja) * 2020-09-10 2024-02-28 シャンシー・ミコ・テクノロジー・カンパニー・リミテッド 二重特異性融合ポリペプチド化合物
US11359134B2 (en) 2020-10-19 2022-06-14 Saudi Arabian Oil Company Treatment fluids and methods for recovering hydrocarbons from a subterranean formation
TW202247854A (zh) * 2021-06-08 2022-12-16 大陸商北京拓界生物醫藥科技有限公司 一種鈣敏感受體激動劑的組成物及其應用
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
WO2025054169A1 (en) * 2023-09-05 2025-03-13 Wake Forest University Health Sciences Compositions and methods for topical treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
WO1992008476A1 (en) * 1990-11-07 1992-05-29 The Scripps Research Institute Peptides that inhibit platelet binding of adhesion molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
EP0917537B1 (en) 1996-07-31 2005-09-07 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
US5895368A (en) 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
WO1998033812A1 (en) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
CN1261281A (zh) * 1997-05-14 2000-07-26 罗纳·布朗克罗尔药制品有限公司 肽甲状旁腺激素类似物
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US20020068342A1 (en) * 2000-02-09 2002-06-06 Rami Khosravi Novel nucleic acid and amino acid sequences and novel variants of alternative splicing
CA2414407A1 (en) 2000-07-18 2002-01-24 Bone Care International, Inc. Stabilized 1.alpha.-hydroxy vitamin d
DE10041126A1 (de) 2000-08-22 2002-04-04 Aventis Res & Tech Gmbh & Co DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
US6855693B2 (en) 2001-01-18 2005-02-15 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of δPKC
WO2002062396A2 (en) 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
BR0207502A (pt) 2001-02-23 2004-03-09 Polyphor Ltd Compostos, enanciÈmeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos
AU2002335668A1 (en) 2001-08-08 2003-02-24 The Research Foundation Of The State University Of New York Muc7d1 peptides as antifungal and antibacterial agents
WO2003013543A1 (en) 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
US7060023B2 (en) 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
US7037897B2 (en) * 2001-10-31 2006-05-02 Abbott Laboratories TRI-, TETRA-, and penta-peptides having antiangiogenic activity
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
EP1576141A4 (en) 2002-05-14 2006-03-22 Bristol Myers Squibb Co NEW HUMAN G-PROTEIN-COUPLED RECEPTORS CODING POLYNUCLEOTIDE AND SPLEISS VARIANTS THEREOF
ATE377023T1 (de) 2003-11-05 2007-11-15 Pevion Biotech Ltd Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target- antigene
KR20070004571A (ko) 2003-12-11 2007-01-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 단백질 키나제 ｃ의 동종효소-특이적 길항제
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US20060052303A1 (en) * 2004-07-27 2006-03-09 Sampath Kuber T Use of thyrotropin for regeneration of bone
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
KR100687932B1 (ko) * 2005-08-09 2007-02-27 삼성전자주식회사 영상표시장치 및 영상표시방법
WO2007027510A2 (en) * 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
CA2669914C (en) * 2006-11-16 2017-11-07 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
KR101775929B1 (ko) 2007-01-19 2017-09-07 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
NZ584048A (en) * 2007-10-02 2012-08-31 Marina Biotech Inc Lipopeptides for delivery of nucleic acids
WO2009075773A2 (en) 2007-12-07 2009-06-18 Goldstein Steven A Identification of toxin ligands
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
LT3192520T (lt) 2009-07-29 2019-06-25 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti paratiroidinio hormono lygių sumažinimui
SI2717896T1 (sl) 2011-06-08 2017-04-26 Kai Pharmaceuticals, Inc. Terapevtska sredstva za reguliranje serumskega fosforja
MX355063B (es) 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.

Similar Documents

Publication Publication Date Title
JP2013155195A5 (enExample)
JP2013500990A5 (enExample)
RU2012107428A (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
US12496350B2 (en) Cyclic peptidyl inhibitors of CAL-PDZ binding domain
JP2013533864A5 (enExample)
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
US12391733B2 (en) Stapled intracellular-targeting antimicrobial peptides to treat infection
CN102300580A (zh) 二肽连接的药剂
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2010515686A5 (enExample)
CN107106642A (zh) 拟肽大环化合物及其制剂
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
CA2968902C (en) Compounds derived from polymyxin
JP2011518179A5 (enExample)
JP2004537581A5 (enExample)
JP2016500682A5 (enExample)
JP2008514586A5 (enExample)
US12157778B2 (en) Peptides for activation of cell signaling in osteoprogenitor cells
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2012506408A5 (enExample)
JP2004521123A5 (enExample)
JP2010536714A5 (enExample)
JP2007535910A5 (enExample)